TEMPE, Ariz., June 9, 2026 — GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients with brain tumors, today announced the closing of an oversubscribed $100 millon Series E equity financing. The financing was led by new investor Viking Global Investors with participation from key existing investors, including MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners and FemHealth Ventures.
“This financing is validation of GammaTile’s potential to be a standard of care treatment for operable brain tumors and will accelerate our ability to bring this important therapy to even more patients,” said Per Langoe, Chief Executive Officer at GT Medical Technologies.
The funds will be used to accelerate investments across commercial and operational initiatives following the release of the final data from the Company’s ROADS randomized controlled trial (RCT) last month. The ROADS RCT studied the use of GammaTile®, the Company’s FDA-cleared bioresorbable radiotherapy implant, in patients with newly diagnosed brain metastases. The ROADS RCT data was selected for oral presentation at the 2026 American Society of Clinical Oncology (ASCO) conference and demonstrated statistical superiority for GammaTile relative to standard of care; GammaTile reduced the risk of tumor recurrence and death at 12 months by 93% and 41%, respectively.